BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock Fundamental Analysis

NASDAQ:BRNS • US91864C1071

0.65 USD
-0.01 (-1.52%)
Last: Feb 19, 2026, 11:08 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BRNS scores 3 out of 10 in our fundamental rating. BRNS was compared to 521 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BRNS as it has an excellent financial health rating, but there are worries on the profitability. BRNS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • BRNS had negative earnings in the past year.
  • In the past year BRNS has reported a negative cash flow from operations.
  • BRNS had negative earnings in 4 of the past 5 years.
  • BRNS had a negative operating cash flow in each of the past 5 years.
BRNS Yearly Net Income VS EBIT VS OCF VS FCFBRNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -55.93%, BRNS is in line with its industry, outperforming 45.30% of the companies in the same industry.
  • BRNS has a Return On Equity (-72.31%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.93%
ROE -72.31%
ROIC N/A
ROA(3y)-23.44%
ROA(5y)-24.68%
ROE(3y)-28.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRNS Yearly ROA, ROE, ROICBRNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BRNS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRNS Yearly Profit, Operating, Gross MarginsBRNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • BRNS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BRNS has more shares outstanding
  • Compared to 5 years ago, BRNS has more shares outstanding
  • BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRNS Yearly Shares OutstandingBRNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BRNS Yearly Total Debt VS Total AssetsBRNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -3.66, we must say that BRNS is in the distress zone and has some risk of bankruptcy.
  • BRNS has a Altman-Z score of -3.66. This is comparable to the rest of the industry: BRNS outperforms 44.72% of its industry peers.
  • BRNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.66
ROIC/WACCN/A
WACC9.33%
BRNS Yearly LT Debt VS Equity VS FCFBRNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • BRNS has a Current Ratio of 8.04. This indicates that BRNS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BRNS (8.04) is better than 74.28% of its industry peers.
  • BRNS has a Quick Ratio of 8.04. This indicates that BRNS is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BRNS (8.04) is better than 74.28% of its industry peers.
Industry RankSector Rank
Current Ratio 8.04
Quick Ratio 8.04
BRNS Yearly Current Assets VS Current LiabilitesBRNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • BRNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.12%.
  • Looking at the last year, BRNS shows a very strong growth in Revenue. The Revenue has grown by 1766.46%.
  • The Revenue has been growing by 16.92% on average over the past years. This is quite good.
EPS 1Y (TTM)-18.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)1766.46%
Revenue growth 3Y282.26%
Revenue growth 5Y16.92%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 1.29% on average over the next years.
  • Based on estimates for the next years, BRNS will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y1.29%
EPS Next 2Y3.23%
EPS Next 3Y1.29%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BRNS Yearly Revenue VS EstimatesBRNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BRNS Yearly EPS VS EstimatesBRNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BRNS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRNS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRNS Price Earnings VS Forward Price EarningsBRNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRNS Per share dataBRNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.23%
EPS Next 3Y1.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BRNS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BARINTHUS BIOTHERAPEUTICS PL

NASDAQ:BRNS (2/19/2026, 11:08:58 AM)

0.65

-0.01 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-18
Inst Owners44.01%
Inst Owner ChangeN/A
Ins Owners13.37%
Ins Owner Change0%
Market Cap26.54M
Revenue(TTM)14.97M
Net Income(TTM)-61.07M
Analysts82.5
Price Target5.61 (763.08%)
Short Float %0%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.39%
Min EPS beat(2)-54.49%
Max EPS beat(2)47.71%
EPS beat(4)1
Avg EPS beat(4)-17.79%
Min EPS beat(4)-54.49%
Max EPS beat(4)47.71%
EPS beat(8)4
Avg EPS beat(8)2.5%
EPS beat(12)6
Avg EPS beat(12)1.34%
EPS beat(16)9
Avg EPS beat(16)31.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)19.35%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.77
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0.37
BVpS2.07
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.93%
ROE -72.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.44%
ROA(5y)-24.68%
ROE(3y)-28.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.95%
Cap/Sales 2.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.04
Quick Ratio 8.04
Altman-Z -3.66
F-Score3
WACC9.33%
ROIC/WACCN/A
Cap/Depr(3y)85.69%
Cap/Depr(5y)117.11%
Cap/Sales(3y)231.54%
Cap/Sales(5y)225.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y1.29%
EPS Next 2Y3.23%
EPS Next 3Y1.29%
EPS Next 5YN/A
Revenue 1Y (TTM)1766.46%
Revenue growth 3Y282.26%
Revenue growth 5Y16.92%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y39.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.68%
EBIT Next 3Y-15.85%
EBIT Next 5YN/A
FCF growth 1Y36.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.16%
OCF growth 3YN/A
OCF growth 5YN/A

BARINTHUS BIOTHERAPEUTICS PL / BRNS FAQ

What is the ChartMill fundamental rating of BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BRNS.


What is the valuation status for BRNS stock?

ChartMill assigns a valuation rating of 0 / 10 to BARINTHUS BIOTHERAPEUTICS PL (BRNS). This can be considered as Overvalued.


How profitable is BARINTHUS BIOTHERAPEUTICS PL (BRNS) stock?

BARINTHUS BIOTHERAPEUTICS PL (BRNS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BRNS stock?

The Earnings per Share (EPS) of BARINTHUS BIOTHERAPEUTICS PL (BRNS) is expected to grow by 1.29% in the next year.